Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Evaluation of ePLAR, the echocardiographic pulmonary to left atrial ratio, in a large cohort with pulmonary hypertension
Scalia, Isabel G. , Ali, Nima Baba , Bismee, Nadera N. , Mahmoud, Ahmed K, Esfahani, Sogol Attaripour , Sheashaa, Hesham, Ibrahim, Oman H, Abdelfattah, Fatmaelzahraa , Barry, Timothy, Tamarappoo, Balaji , Scott, Robert L, Rosenthal, Julie , Lester, Steven J, Ayoub, Chadi, Arsanjani, Reza, Mahmoud, Ahmed , Scalia, Isabel G , Pietri, Milagros Pereyra, Awad, Kamal , Javadi, Niloofar , Mahmoud, Ahmed K , Tamarappoo, Balaji K, Alsidawi, Said , Ayoub, Chadi , Farina, Juan M. , Pereyra, Milagros , Abbas, Mohammed Tiseer , Awad, Kamal , Barry, Timothy , Alsidawi, Said , Scott, Robert L. , Lester, Steven J., Arsanjani, Reza

Mayo Clinic

European Heart Journal Open | December 18, 2025 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/ehjopen/oeaf174 | PMID 42282056 Get It

Abstract Aims Pre-capillary pulmonary hypertension (PHTN), typically due to intrinsic pulmonary pathology, requires right heart catheterization (RHC) for diagnosis. ePLAR, the echocardiographic pulmonary to left atrial ratio [calculated: tricuspid regurgitation maximum velocity (TRVmax) divided by mitral valve E to e′ wave ratio (E/e′)], has been demonstrated as a promising non-invasive surrogate for characterization of pre-capillary PHTN. As such, this study aimed to further evaluate the diagnostic utility of ePLAR in a large cohort of patients with PHTN. Methods and results All RHCs between 2018 and 2023 across three tertiary centres were retrospectively reviewed. Patients with PHTN were characterized as pre-capillary or post-capillary (isolated or combined). Concurrent ePLAR was calculated. ROC analysis evaluated the accuracy of ePLAR in detecting pre-capillary PHTN. Overall, 2235 patients had PHTN by RHC, mean age 63.5 ± 14.7 years, 53.5% male. Of these, 43.3% had pre-capillary PHTN. ROC analysis demonstrated ePLAR to have good accuracy in detection of pre-capillary PHTN (AUC 0.760), with a cutoff of 0.20 m/s demonstrating a sensitivity and specificity of 77% and 60% respectively. This persisted on sensitivity analysis for contemporaneous investigations and for right ventricular function. Conclusion In this large cohort, ePLAR was validated as an accurate tool for identifying patients with pre-capillary PHTN. This widely available, non-invasive, and reproducible parameter can have an important role in the work up of PHTN and may guide the need for invasive testing.
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025
Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa, Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pappo, Alberto S., Pollack, Seth M., Poppe, Matthew, Riedel, Richard F., Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat, Pappo, Alberto S. , Riedel, Richard F. , Riedel, Richard F , Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa Anne , Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pollack, Seth M., Poppe, Matthew, Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 498-506

10.6004/jnccn.2025.0058 | PMID 41671462 Get It

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Wang, Yucai , Hwang, Steven R. , Villa, Diego , Kugathasan, Laveniya , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor , Hill, Brian T. , Bond, David A. , Maddocks, Kami J. , Nizamuddin, Imran , Danilov, Alexey V. , Argao, Christine, Ruan, Jia , Khan, Nazneen B., Ouchveridze, Evguenia, Mou, Eric , Pongas, Georgios , Lossos, Izidore S. , Harris, Zoey I., Young, Philip, Greenwell, Irl Brian , Gerber, Drew G. , Wang, Michael , Narkhede, Mayur , Stack, Anthony , Messmer, Marcus , Moyo, Tamara K. , Anna, Jacob, Stanisic, Alexander , Cohen, Jonathon B. , Hwang, Steven R , Villa, Diego , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor R , Bond, David A , Kahl, Brad S , Ryan, Christine E , Grover, Natalie S , Tun, Aung M , Mou, Eric , Lossos, Izidore S , Moustafa, Muhamad Alhaj , Pophali, Priyanka , Gerber, Drew , Jain, Preetesh , Wang, Michael L , Narkhede, Mayur S , Mehta, Amitkumar , Stack, Anthony C , Bhansali, Rahul S , Barta, Stefan K , Ghosh, Nilanjan , Kamdar, Manali , Stanisic, Alexander V , Karmali, Reem , Maurer, Matthew , Cerhan, James R , Cohen, Jonathon B , Wang, Yucai , Larson, Melissa C. , Kahl, Brad S. , Ryan, Christine E. , Merryman, Reid W. , Grover, Natalie S. , Ouchveridze, Evguenia, Tun, Aung M. , Ayyappan, Sabarish Ram , Muñoz, Javier , Portell, Craig A. , Baidoun, Firas , Moustafa, Muhamad Alhaj , Reagan, Patrick Michael , Banaszak, Lauren Gabriele , Pophali, Priyanka A. , Velayati, Arash , Jain, Preetesh , Mehta, Amitkumar , Bhansali, Rahul S. , Kamdar, Manali , Anna, Jacob, Karmali, Reem , Maurer, Matthew J. , Cerhan, James R. , Martin, Peter

Mayo Clinic

Blood Advances | December 11, 2025 | Volume: 10 | Issue: 4 | Pages: 1372-1380

10.1182/bloodadvances.2025018527 | PMID 41380101 Get It

Abstract The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.
Glucagon‐Like Peptide‐1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction
Ibrahim, Ramzi , Han, William , Wang, Winston , Kau, Ethan , Said, Nada, Forst, Beani, Pham, Hoang Nhat , Abdelnabi, Mahmoud , Salih, Mohammed , Ali, Nima Baba , Lester, Steven J., Ayoub, Chadi , Nhat, Hoang , Baba Ali, Nima , Lee, Kwan S , Ayoub, Chadi , Arsanjani, Reza , Ibrahim, Ramzi , Salih, Mohammed , Farina, Juan M. , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Journal of the American Heart Association | December 11, 2025 | Volume: 14 | Issue: 24 | Pages: No page available

10.1161/jaha.125.044577 | PMID 41378487 Get It

Background To compare the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus bariatric surgery on cardiovascular outcomes in patients with heart failure (HF) with preserved ejection fraction and obesity. Methods Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m 2 ) from 2017 to 2022. Patients were categorized into 2 cohorts: those receiving GLP‐1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery. Propensity score matching (1:1) was used to balance baseline characteristics. Primary outcomes included acute HF events and all‐cause hospitalizations. Secondary outcomes included all‐cause death, myocardial infarction, stroke, and follow‐up body mass index. Cox proportional hazard models were used to estimate hazard ratios (HRs). Results A total of 2747 patients were included per cohort (mean age, 68 years). GLP‐1 RA therapy was associated with lower incidence of acute HF events (38.9% versus 44.6%; HR, 0.78 [95% CI, 0.72–0.85]), all‐cause death (11.1% versus 14.8%; HR, 0.71 [95% CI, 0.61–0.82]), and all‐cause hospitalizations (66.4% versus 77.3%; HR, 0.62 [95% CI, 0.58–0.66]). Rates of myocardial infarction (13.8% versus 13.4%; HR 0.99 [0.86–1.14]) and stroke (9.7% versus 10.7%; HR, 0.87 [0.74–1.02]) were similar between groups. Mean body mass index at follow‐up was 38.0 in the GLP‐1 RA cohort versus 37.7 after bariatric surgery ( P =0.34). Hemoglobin A 1c at follow‐up was higher in the GLP‐1 RA group (7.4 versus 6.8; P <0.001). Conclusions In patients with HF with preserved ejection fraction and obesity, GLP‐1 RA therapy was associated with improved outcomes compared with bariatric surgery, supporting the need for prospective trials to evaluate GLP‐1 RAs as a therapeutic alternative.
Capitate morphology as a risk factor for healing in scaphoid non-union
Hsu, Cheng-En , Vilai, Parunyu, Wan, Rou , Moran, Steven L. , Moran, Steven L , Vilai, Parunyu , Zhao, Chunfeng

Mayo Clinic

Journal of Hand Surgery (European Volume) | December 8, 2025 | Volume: 51 | Issue: 4 | Pages: 428-437

10.1177/17531934251399509 | PMID 41355072 Get It

Introduction: This study investigated the association between capitate morphology and the success rates of non-vascularized bone graft (NVBG) and vascularized bone graft (VBG) operations for scaphoid nonunion. Methods: We retrospectively analysed 213 patients with established scaphoid non-union who underwent either non-vascularized bone graft ( n = 75) or vascularized bone graft ( n = 138). We analysed risk factors, including demographics, medical history, implant type, previous surgery, bone graft donor site and capitate morphology for their association with treatment outcome. We also assessed the relationship between capitate and scaphoid morphology in the uninjured wrists of 31 patients. Results: The overall success rate was 81% for NVBG and 86% for VBG, with no significant difference. For NVBG, Type II capitate, age 40 or older and tobacco use were significant risk factors for failure. For VBG, only previous surgery was a significant risk factor. In uninjured wrists, a Type II capitate was associated with a significantly thinner scaphoid waist and a lower waist index than a Type I capitate. Conclusion: Our study introduces a new radiographic classification of capitate morphology and establishes its significant association with scaphoid morphology. Beyond traditional factors, capitate morphology can help to assess scaphoid morphology and potentially infer vascularity, aiding the selection of the most appropriate bone graft type for treating scaphoid non-union. Level of evidence: III
Contemporary survival trends in patients with adult T-cell leukemia/lymphoma (ATLL) in the United States: Insights from the national cancer database
Toumeh, Nadia , Marar, Rosalyn, Day, Jonathan R , Yu, Tao , Zhou, Jihao , Hwang, Steven R. , Wang, Yucai , Godby, Richard

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1871-1871

10.1182/blood-2025-1871 Get It

Abstract Introduction: Adult T-cell leukemia/lymphoma (ATLL) is a rare blood disorder associated with human T-cell leukemia virus type 1 (HTLV-1) infection. It is generally categorized into four subtypes: smoldering, chronic, lymphoma, and acute. Given the heterogeneity of these subtypes, there is a significant difference in outcomes. Robust and contemporary epidemiological data are lacking for this rare disorder. We present a retrospective cohort study of patients with ATLL, utilizing the National Cancer Database (NCDB) to better characterize the epidemiology and survival trends in the United States. Methods: This is a retrospective cohort study using the NCDB to identify ATLL cases diagnosed from 2004-2020. Descriptive statistics summarized baseline characteristics, while chi-square tests assessed group differences. Overall survival (OS) was estimated using Kaplan-Meier analysis and compared using log-rank tests. Multivariable Cox proportional hazards models identified independent prognostic factors (p &lt; 0.05 considered significant). Results: A total of 635 patients were identified with ATLL, including 344 (54%) males and 291 (46%) females, with a median age at diagnosis of 59 years (range: 19-90). Most patients came from the Middle Atlantic (NY, NJ, PA) region (33%), followed by the South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV) region (20%) and the East North Central (IL, IN, MI, OH, WI) region (8%). Of the 635 patients, 335 (52%) were Black, 247 (39%) White, and 26 (4%) Asian. Sixty-five (10%) patients were of Hispanic origin. Over half of patients with ATLL (54%) had a median income below $46,000. International Prognostic Index (IPI) score was only available for 16 patients: three (19%) patients were in the high-risk group, 7 (43%) in the high-intermediate group, and 6 (37.5%) in the low-intermediate group. Treatment groups included 357 (56%) patients treated with chemotherapy and 29 (4.5%) who received radiation therapy. Thirty-three (5%) patients underwent hematopoietic stem cell transplant (HSCT), including 27 autologous and 16 allogeneic transplants. The median survival time in the cohort was 9 months (95% CI 7.3-10.7). One-year OS rate in the cohort was 43%, while 2-year and 5-year OS rates were 31% and 23.5%, respectively. Patients over the age of 65 had a significantly shorter median OS than those under 65 (4 vs. 11 months, p=0.001) and were significantly less likely to undergo HSCT (p&lt; 0.001). Black patients had significantly shorter median OS compared to White patients (7.8 months vs 13.3 months, p=0.014), despite similar treatment rates with chemotherapy and HSCT. Median OS appeared to improve over time, from 8 months in patients diagnosed between 2004-2009 to 10 months for those diagnosed between 2016-2020, although this was not statistically significant (p=0.145). Treatment with allogeneic HSCT was associated with significantly prolonged median survival, compared to those who did not receive transplant (50 months vs. 7 months, p&lt;0.05). Additionally, receiving chemotherapy and/or radiation compared to not receiving treatment was also associated with significantly prolonged median survival (p&lt;0.05). Patients treated in the Middle Atlantic region had a median survival of 8.8 months, compared to 23.2 months in the West South Central (AR, LA, OK, TX) region (p&lt; 0.001). Increased education and income levels were not significantly associated with improved survival. There were no significant differences in survival between males and females. Conclusions: We provide contemporary estimates on the epidemiology of ATLL. Factors associated with improved prognosis included undergoing HSCT, radiation, or chemotherapy. We report that increased age and Black race are negative prognostic factors. Regional differences in incidence and survival persist in the US. Our study findings underscore the need for increasing access to treatment, including HSCT for those who are good candidates. Additionally, there remains work to be done to address racial disparities in the care of patients with ATLL.
Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes
Tessier, Steven , He, Rong , Abdelmagid, Maymona, Rud, Danielle, Al‐Kali, Aref , Gangat, Naseema , Patnaik, Mrinal M. , Mangaonkar, Abhishek A. , Anani, Hosein, Punwani, Nathan , Foran, James M. , Gnanamanickam, Emmanuel , Ladon, Dariusz, Begna, Kebede, Matin, Aasiya , Reichard, Kaaren K. , Zepeda, Cinthya Mendoza, Tefferi, Ayalew, Hiwase, Devendra , Hung, Kevin , Maritz, Michelle F. , Anani, Hosein, Saliba, Antoine N. , Chen, Dong , Alkhateeb, Hassan B. , Kutyna, Monika , Scott, Hamish S. , Hefazi, Mehrdad , Hahn, Christopher N , Hogan, William J. , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow , Shah, Meera , Tefferi, Ayalew

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2087-2087

10.1182/blood-2025-2087 Get It

Abstract Background: TP53-mutated myeloid neoplasms (MNs) represent one of the most lethal subgroups of blood cancers. The World Health Organization (WHO-5) recognize TP53-mutated (TP53mut) myelodysplastic syndrome (MDS) and International Consensus Classification (ICC) recognize TP53mut MDS and acute myeloid leukaemia (AML) as distinct disease entities, acknowledging their dismal prognosis and the urgent need for novel therapeutic strategies. However, key discrepancies exist between the classifications, creating uncertainty in diagnosis, influencing therapeutic decisions, and complicating clinical trial enrolment for patients with uniformly poor survival. Importantly, neither classifications included TP53-mutated myelofibrosis (MF), other myeloproliferative neoplasms (MPN), and MDS/MPN overlap syndromes, despite growing evidence that these cases carry similar adverse outcomes. To address these critical gaps, we conducted a comprehensive analysis across the full spectrum of TP53-mutated MN. Methods: We included TP53mut cases with variant allele frequency (VAF ≥2%) of AML, MDS, MDS/MPN overlap, myelofibrosis and other MPN managed at the Mayo clinic (Rochester, USA) and Local Health Network in South Australia (Australia). Cases were classified according to the revised 4th edition WHO classification (WHO-4R). Biallelic TP53 loss was defined as: (i) ≥2 mutations with VAF ≥2%; (ii) single TP53mut with VAF ≥2% plus 17p loss on karyotype, FISH, or SNP array; or (iii) single TP53mut with VAF ≥50% with or without 17p loss. Monoallelic loss was defined as a single TP53mut with VAF &lt;50% without 17p loss or copy neutral loss of heterozygosity. The primary endpoint was overall survival (OS) from diagnosis, censored at allogeneic transplantation. Conditional inference tree analysis was performed to define the effect of individual predictors on OS. Results: We identified 853 TP53mutMN cases including WHO-4R-defined AML (BM/PB blasts ≥20%, n=314; 36.8%), MDS with excess blasts-2 (EB-2; BM 10–19% or PB 5–19%, n=129; 15.1%), MDS-EB-1 (BM 5–9% or PB 2–4%, n=100; 11.7%), and MDS with low blasts (LB; BM &lt;5% and PB &lt;1%, n=228; 26.7%). MF included chronic phase (MF-CP, n=48; 5.6%), accelerated phase (MF-AP, n=7; 0.8%), and blast phase (MF-BP, n=17; 2.0%). Additional cases comprised other MPN-chronic phase (n=3, 0.4%) and MDS/MPN overlap syndromes (n=7, 0.8%). Of 848 evaluable TP53mut MN, 616 (72.6%) harbored biallelic TP53 loss and 232 (27.4%) had monoallelic loss, with 42.4% (n=98) of monoallelic cases harboring a complex karyotype (CK). Biallelic loss was highly prevalent in AML (83.1%), MDS (70.4%), and MDS/MPN overlap (71.4%), but was less frequent in cases with MPN (33.3%) and MF-chronic phase (25.0%). Across the spectrum, the frequency of biallelic loss increased stepwise with disease progression, rising from MDS-LB (62.8%) to MDS-EB1 (76.0%), MDS-EB2 (79.5%), AML (83.1%), and MF-AP/BP (79.2%) (P&lt;0.0001). In multivariable analysis, WHO-4R category, TP53mut VAF, biallelic loss and CK were independent predictors of poor survival in TP53mut MN. Conditional inference tree analysis stratified the cohort into seven prognostic groups with distinct median OS: (1) AML, MF-BP/AP, and MDS/MPN overlap regardless of mono/biallelic and CK status (n=335, 39.7%; median OS 4.0 months); (2) MDS-EB1/EB2 with biallelic loss or monoallelic plus CK (n=212, 25.1%; 7.2 months); (3) MDS-LB, MF-CP and MPN with CK (n=156, 18.5%, OS 10.2 months); (4) biallelic MDS-LB (n=28, 3.3%; OS 15.6 months), (5) monoallelic MDS-EB1/EB2 without CK (n=20, 2.4%; OS 26.2 months), (6) monoallelic MDS-LB without CK (n=57, 6.7%; OS 33.4 months), and (7) MF-CP and other MPN without CK (n=36, 4.3%; OS 37.0 months). This analysis defines a clear stepwise risk gradient, identifying subsets with extremely poor prognosis versus a relatively indolent disease. Conclusions: This is the first study to evaluate the prognostic impact of TP53mut MN across the entire MN spectrum, providing a framework for future refinement of TP53-driven disease classification. Key findings include: (i) MF-AP/BP and MDS/MPN overlap exhibit survival outcomes as dismal as AML, irrespective of the TP53 allele status; and (ii) complex karyotype is a surrogate for “biallelic equivalent”, refining risk interpretation in monoallelic cases. Overall, our study defines seven prognostic subgroups spanning all TP53mut MN, offering a foundation for risk-adapted clinical trial design and future classification updates.
Capitate Morphology: A New Radiographic Association with Preiser's Disease
Hsu, Cheng-En , Vilai, Parunyu , Wan, Rou , Zhao, Chunfeng , Moran, Steven L.

Mayo Clinic

Journal of Wrist Surgery | December 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2745-8586 Get It

Abstract Preiser's disease (PD), or idiopathic avascular necrosis of the scaphoid, is a debilitating condition leading to wrist pain, dysfunction, and pan-carpal arthritis. While impaired scaphoid vascularity is central to its pathogenesis, identifying individuals at risk is challenging due to the morphological distortion of the scaphoid as the disease progresses. This study aims to investigate the association between a novel capitate morphology classification, scaphoid morphology, and their impact on PD prevalence and characteristics. We also re-evaluate negative ulnar variance (NUV) as a potential risk factor for PD. This retrospective case–control study included 34 PD patients and 340 age-matched controls. Capitate morphology was classified into Type I/II on anteroposterior (AP) radiographs based on capitotrapezoid–scaphocapitate (CT–SC) joint line angle and ratio. Scaphoid morphology was assessed via the waist index on contralateral healthy wrists. Radiographic measurements of ulnar variance and PD staging were also performed. Statistical analyses compared morphological prevalence and risk factors between groups. Type II capitate was significantly more prevalent in the PD group (35.3%) than in controls (17.1%, p = 0.018). Similarly, NUV was significantly higher in PD patients (29%) compared with controls (6.8%, p < 0.001). We found a strong correlation between Type II capitate and slender (Type II) scaphoid morphology in healthy wrists. No significant differences in age, gender, or affected side were observed. Interobserver and intraobserver agreements for capitate classification were substantial (kappa ≥0.882). Our study introduces a reliable radiographic method for classifying capitate morphology, which strongly correlates with intrinsic scaphoid shape and potential vascular vulnerability. Both Type II capitate morphology and NUV are significant predisposing factors for PD. These findings offer valuable insights for identifying at-risk individuals and improving understanding of PD's multifactorial etiology. Diagnostic Level III.
ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features
Tessier, Steven , Ali, Najla Al, Trinh, Michael , Brunner, Andrew M. , Sallman, David A. , Padron, Eric , Foran, James M. , Yi, Cecilia Y. Arana , Al‐Kali, Aref , Ali, Najla Al , Fontana, Diletta , Gambacorti-Passerini, Carlo B , Piazza, Rocco , Xie, Zhuoer , Yi, Cecilia Arana , Alkhateeb, Hassan B. , Shah, Meera , Komrokji, Rami S.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3864-3864

10.1182/blood-2025-3864 Get It

Abstract Background: Mutations in ethanolamine kinase-1 (ETNK1) have been identified in a wide range of myeloid neoplasms (MN), but their clinical significance remains poorly defined. Key gaps remain, including the true prevalence, variant- and disease-specific co-mutation patterns, cytogenetic patterns, and prognostic impact, highlighting the need for broader multi-institutional studies to refine our understanding and risk stratification. We present findings from an ongoing multi-institutional study of ETNK1-mutated (ETNK1mut) MN. Methods We analyzed 106 patients with ETNK1mut MN across the Mayo Clinic Comprehensive Cancer Center (Minnesota, Arizona, and Florida), H. Lee Moffitt Cancer Center (Tampa, FL), Massachusetts General Hospital (Boston, MA), and University of Milano-Bicocca (Monza, Italy), integrating clinical, hematologic, cytogenetic, and next-generation sequencing (NGS) data. Appropriate IRB approval was obtained. Diagnoses were assigned by the 5th edition of the World Health Organization and 2022 European LeukemiaNet criteria. A clone was considered dominant if it had the highest variant allele frequency (VAF) or VAF within 5% of the highest co-mutation. Overall survival (OS) was assessed by Kaplan-Meier. Comparison cohorts for OS included 83 ETNK1 wild-type (ETNK1wt) myelodysplastic syndrome (MDS) and 415 ETNK1wt acute myeloid leukemia (AML) patients without TP53 mutations. GraphPad Prism v10 was used for statistical analysis. Results Median age at diagnosis was 70 years (range 30.4-90), with a male predominance of 72.6% (n=77). ETNK1mut were identified in MDS (n=47, 44.3%), myelodysplastic/myeloproliferative neoplasms (MDS/MPN; n=23, 21.7%), myeloproliferative neoplasms (MPN; n=13, 12.3%), AML (n=12, 11.3%), clonal cytopenia of undetermined significance (CCUS; n=5, 4.7%), and other entities (n=6, 5.7%) including atypical chronic myeloid leukemia (n=1) and systemic mastocytosis (n=1). Over a median follow-up of 33.6 months (IQR 15-91.8), 49.1% (n=52) patients died and 19.4% (n=18 of 93 at risk) progressed to AML. Cytogenetics were available in 103 patients; 57.3% (n=59) had a normal karyotype, while 30.1% (n=31) had abnormal and 12.6% (n=13) had complex karyotypes. None harbored classical MDS-associated deletions such as del(5q), del(7q), or del(20q). The most frequent cytogenetic abnormalities included translocations (n=17), monosomy 7 (n=9), and trisomy 8 (n=8). Of 17 translocations, 8 (47%) involved chromosome 1, two of which (11.8%) involved der(1;7)(q10;p10). The most common ETNK1 mutation was N244S (n=70, 66.0%), followed by K378N (n=12, 11.3%) and G245 variants (n=9, 8.5%), including G245V and G245D. VAF data were available for 103 patients; the median ETNK1 VAF was 31.4% (range 2.0-54.8%). High VAF (≥40%) was observed in 27.2% (n=28) of patients. ETNK1 was the dominant mutation in 33% (n=34) of cases, shared equal dominance with a co-mutation in 13% (n=14), and was a subclone in 56% (n=58). Co-mutations were detected in 77% (n=82) of patients, with a median of 4 (range 0-13) co-mutated genes. A third of patients (n=37, 35%) had ≥5 co-mutations. The most frequently co-mutated genes were epigenetic regulators including ASXL1 (n=29, 27%), TET2 (n=17, 16%), EZH2 (n=12, 11%), and DNMT3A (n=12, 11%), followed by splicing factor genes including U2AF1 (n=13, 12%), SRSF2 (n=10, 9%), and ZRSR2 (n=10, 9%). Mutations in signaling genes (JAK2, NRAS, SETBP1) and transcription factors (RUNX1, BCOR) were also observed. High VAFs were seen in co-mutations of EZH2 (median 49%), TET2 (46%), and NRAS (46%). ASXL1 was most enriched in MDS/MPN (n=8, 35%) and MPN (n=3, 23%). Survival analysis showed better survival in ETNK1mut compared to ETNK1wt within AML (65 vs 19 months; p=0.2002) and MDS (107 vs 61 months; p=0.1993), although statistical significance was not reached. Conclusion ETNK1 mut frequently co-occur with mutations in epigenetic and splicing regulators, and demonstrate distinct molecular and cytogenetic features, including the absence of classic MDS-associated deletions and a high prevalence of translocations involving chromosome 1. ETNK1 was the dominant clone in a third of cases with a high co-mutation burden. Overall survival was better in ETNK1mut AML and MDS, but the difference was not statistically significant. These findings highlight the need for larger collaborative studies.
Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression
Tessier, Steven , Jabban, Yazan Khair Eldien , Patnaik, Mrinal M. , Ongie, Laura , Mangaonkar, Abhishek A. , Gangat, Naseema , Foran, James M. , Punwani, Nathan , Kusne, Yael , Begna, Kebede, Tefferi, Ayalew , Al‐Kali, Aref , Jabban, Yazan, Alkhateeb, Hassan B. , Hogan, William J. , Saliba, Antoine N. , Badar, Talha , Murthy, Hemant S. , Yi, Cecilia Arana , Hiwase, Devendra , Shah, Meera

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5643-5643

10.1182/blood-2025-5643 Get It

Abstract Background: TP53-mutated (TP53mut) myeloid neoplasms (MN) are a biologically and clinically distinct subgroup of blood cancers associated with extremely poor outcomes and limited response to conventional therapies. In some patients, MN are preceded by clonal cytopenia of undetermined significance (CCUS). Prior cytotoxic exposure (treatment related, TR) is an independent predictor for survival in CCUS (Li et al, Blood Adv. 2024). As TP53mut CCUS and MN are enriched in TR cases, the interaction between cytotoxic exposure and TP53mut status on the risk of progression and survival remains unclear. Methods: Adult patients with CCUS who were evaluated at the Mayo Clinic or South Australian myelodysplastic syndrome (MDS) Registry (Adelaide, Australia) were included. CCUS and MDS were defined according to the 5th edition of the WHO classification for MN (Khoury et al, 2022), except for the exclusion of cases harboring MDS-defining cytogenetics. Next-generation sequencing was performed using a targeted panel covering genes commonly mutated in MN. In cases with &gt;1 TP53mut, VAFs were summed. Survival outcomes were assessed by Kaplan-Meier with log-rank testing. Univariate and multivariate analyses were estimated using Cox proportional hazards regression. Results: Of 320 CCUS cases, 50 (15.6%) harbored TP53mut (TP53mut CCUS), whereas 270 (84.4%) were wild-type (TP53wt CCUS). Median age at diagnosis was 71 years (range 16-99). TP53mut CCUS had a greater proportion of females (60% vs 33.7%, p&lt;0.001) and TR (66% vs 23%, p&lt;0.001) compared to TP53wt. Hematologic parameters including hemoglobin, red cell distribution width, mean corpuscular volume, white blood count, absolute neutrophil count, platelets, and bone marrow blasts were comparable between the two groups. Almost all TP53mut (n=48, 96%) were located in the DNA-binding domain and the median variant allele frequency (VAF) was 9% (range 2-46%). Five (10%) cases harbored 2 TP53mut. The distribution of TP53mut VAF among patients was as follows: ≤2.5% (n=2), 2.5-5% (n=10), 5-10% (n=19), 10-20% (n=11), and ≥20% (n=7). The proportion of cases with cytogenetic abnormalities was smaller in TP53mut compared to TP53wt CCUS(12% vs 25.9%, p=0.035). Both cohorts had a comparable median number of mutations: 2 (range 0-7) in TP53mut and 2 (range 0-5) in TP53wt. The most common co-mutations in TP53mut CCUS were TET2 (n=8, 17.8%), PPMD1 (n=7, 15.6%), DNMT3A (n=6, 13.3%), ASXL1 (n=6, 13.3%), and SRSF2 (n=4, 8.9%). At last follow up, the rate of progression was comparable between TP53mut and TP53wt CCUS (12% vs 22%, p=0.13). Median time to MN progression was not reached in TP53mut and 6.25 months in TP53wt CCUS (p=0.5197). A significantly higher proportion of TP53mut cases acquired complex cytogenetics compared to TP53wt cases (33% vs 2%, p=0.024) at MN progression. Of 20 deaths observed in the TP53mut cohort, non-myeloid hematologic malignancies (n=6, 30%), infections (n=5, 25%), and TP53mut MN (n=4, 20%) were the 3 most common causes. With a median follow-up of 4 years (IQR 1.2-4.8), median OS was longer in de novo (dn) cases (8.7 years for dn TP53wt; not reached for dn TP53mut) and shorter in TR cases (3.3 years for TR TP53wt; 4.8 years for TR TP53mut). Notably, TP53mut showed no independent prognostic impact in the entire cohort, or when stratified by TR vs dn CCUS. On multivariate analysis that included TP53mut status, factors independently associated with inferior OS included prior therapy (HR 2.21, 95% CI 1.41-3.45, p&lt;0.001), anemia (HR 4.1, 95% CI 1.88-8.99, p&lt;0.001), and thrombocytopenia (HR 2.38, 95% CI 1.43-3.95, p&lt;0.001). Similarly, TR CCUS (HR 1.6, 95% CI 1.06-2.4, p=0.03) and anemia (HR 2.15, 95% CI 1.25-3.7, p=0.006) were independently associated with inferior progression free survival. Conclusion: TP53 mut in CCUS did not independently predict inferior survival or increase leukemic transformation. While TP53mut CCUS were less likely to harbor cytogenetic abnormalities at diagnosis, significantly more cases harbored genomic instability at leukemic transformation. The poor outcomes attributed to TP53mut CCUS were driven by prior cytotoxic exposure, cytopenia – particularly anemia, and non-leukemic causes of death. These findings suggest risk stratification in CCUS should prioritize clinical context over TP53mut status alone.